

ASX RELEASE

28 February 2023

**KAZIA THERAPEUTICS LIMITED (ASX: KZA; NASDAQ: KZIA) - CLEANSING NOTICE**

This notice is given by Kazia Therapeutics Limited (**Kazia**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

On 28 February 2023, Kazia has issued 15,522,075 fully paid ordinary shares (**New Shares**) to professional and sophisticated investors at an issue price of \$0.11 per New Share, as foreshadowed in its placement announced on 16 January 2023.

In accordance with section 708A(6) of the Corporations Act, Kazia advises that:

- (a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, Kazia has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to Kazia; and
  - (ii) section 674 of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is "excluded information" within the meaning of sections 708A(7) or 708A(8) of the Corporations Act.

Yours sincerely



Kate Hill  
Company Secretary  
Kazia Therapeutics Limited

**Board of Directors**

**Mr Iain Ross** Chairman, Non-Executive Director  
**Mr Bryce Carmine** Non-Executive Director  
**Mr Steven Coffey** Non-Executive Director  
**Dr James Garner** Chief Executive Officer, Managing Director